Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Children's Hospital of Soochow University
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06221683CT.gov Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML | — | Recruiting | — | — | — |
NCT05313958CT.gov Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children | — | Unknown | — | — | — |
NCT04326439CT.gov AflacLL1901 (CHOA-AML) | — | Terminated | — | — | — |
NCT02638428CT.gov Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | — | Unknown | — | — | — |
NCT01576185CT.gov Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01445080CT.gov Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sorafenib (this asset) | Children's Hospital of Soochow University | P2/3 | B · 61 |
| Etoposide | Joanna Yi | P3 | BBB |
| Cytarabine | Children's Oncology Group | P3 | BBB |
| Nivestim | National Cancer Institute (NCI) | P3 | BBB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P3 | BBB |
| Methotrexate | Children's Oncology Group | P3 | BBB |
| Fludarabine | National Cancer Institute (NCI) | P3 | BB |
| Cyclosporin A | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P3 | BB |
| Idarubicin | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P3 | BB |
+42 more in the Childhood Acute Myeloid Leukemia cohort
Other indications for Sorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P4 | BBB · 79 |
| Portal Vein Thrombosis | — | P4 | BBB · 74 |
| Adult Hepatocellular Carcinoma | — | P3 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sorafenib in Childhood Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sorafenib-childhood-acute-myeloid-leukemia-21635
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →